Neoadjuvant Therapy in Biliary Adenocarcinoma

    Not Recruiting
  • End date
    Feb 4, 2029
  • participants needed
  • sponsor
    Jordan Kharofa
Updated on 28 April 2022


Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.


This trial will evaluate whether a neoadjuvant paradigm is feasible in resectable biliary adenocarcinoma. All components of therapy are currently used standards of care, however they have not been used in the neoadjuvant setting for the management of resectable biliary cancers. The study will use Gemcitabine/cisplatin, followed by chemoradiation.

This is a feasibility trial with an accrual goal of 12 patients using the primary endpoint of completion of neoadjuvant therapy and surgery as an assessment of feasibility.

Condition Adenocarcinoma, Malignant Adenoma, Adenocarcinoma, Cholangiocarcinoma, Biliary neoplasm, Biliary Tract Cancer, Urothelial Tract Cancer, Urothelial Tract Cancer, Malignant Adenoma, Biliary Tract Cancer, biliary cancer
Treatment fluorouracil, cisplatin, Gemcitabine, Short course ChemoRT
Clinical Study IdentifierNCT04480190
SponsorJordan Kharofa
Last Modified on28 April 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note